Production (Stage)
Xenon Pharmaceuticals Inc.
XENE
$29.75
-$0.74-2.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 0.97% | -4.61% | -8.40% | -20.85% | -7.13% |
| Total Depreciation and Amortization | 4.11% | -5.38% | 1.52% | 12.46% | 193.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 76.08% | -28.66% | -18.02% | 103.98% | -30.50% |
| Change in Net Operating Assets | -657.31% | 340.18% | -109.03% | 269.59% | -2,232.94% |
| Cash from Operations | -13.36% | -6.33% | -56.51% | 29.25% | -30.47% |
| Capital Expenditure | 94.51% | -32.71% | 61.03% | -705.32% | -141.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -65.20% | 3,763.27% | -97.71% | 360.98% | 82.06% |
| Cash from Investing | -64.97% | 4,874.90% | -98.21% | 356.34% | 81.99% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -90.51% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -90.51% | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | 94.47% | -2,242.59% | 126.73% | 44.96% | -249.19% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -147.29% | 212.17% | -163.10% | 186.73% | -282.90% |